billion,3 up 41 percent over 2009, and, for the first time, we achieved more than $1 billion of annual revenue in both China and Brazil. During 2010 close interaction among our development, medical, external affairs and commercialization teams helped boost registrations for Prevnar 134 for pediatric use to more than 80 countries and launches to more than 55 countries. This new vaccine, which helps…
Words 3254 - Pages 14